PL365927A1 - Kompozycje agonistów GABA i inhibitorów dehydrogenazy sorbitolowej - Google Patents

Kompozycje agonistów GABA i inhibitorów dehydrogenazy sorbitolowej

Info

Publication number
PL365927A1
PL365927A1 PL01365927A PL36592701A PL365927A1 PL 365927 A1 PL365927 A1 PL 365927A1 PL 01365927 A PL01365927 A PL 01365927A PL 36592701 A PL36592701 A PL 36592701A PL 365927 A1 PL365927 A1 PL 365927A1
Authority
PL
Poland
Prior art keywords
combination
dehydrogenase inhibitors
sorbitol dehydrogenase
gaba agonists
gaba
Prior art date
Application number
PL01365927A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL365927A1 publication Critical patent/PL365927A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL01365927A 2000-11-30 2001-11-19 Kompozycje agonistów GABA i inhibitorów dehydrogenazy sorbitolowej PL365927A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30
PCT/IB2001/002213 WO2002043762A2 (en) 2000-11-30 2001-11-19 Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Publications (1)

Publication Number Publication Date
PL365927A1 true PL365927A1 (pl) 2005-01-10

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365927A PL365927A1 (pl) 2000-11-30 2001-11-19 Kompozycje agonistów GABA i inhibitorów dehydrogenazy sorbitolowej

Country Status (38)

Country Link
US (1) US6544998B2 (pl)
EP (1) EP1337271B1 (pl)
JP (1) JP2004514699A (pl)
KR (1) KR20030059290A (pl)
CN (1) CN1477975A (pl)
AP (1) AP2001002360A0 (pl)
AR (1) AR031431A1 (pl)
AT (1) ATE281181T1 (pl)
AU (1) AU2002215159A1 (pl)
BG (1) BG107774A (pl)
BR (1) BR0115783A (pl)
CA (1) CA2430298A1 (pl)
CR (1) CR6964A (pl)
CZ (1) CZ20031399A3 (pl)
DE (1) DE60106968T2 (pl)
DO (1) DOP2001000289A (pl)
EA (1) EA200300432A1 (pl)
EC (1) ECSP034624A (pl)
EE (1) EE200300248A (pl)
ES (1) ES2230378T3 (pl)
HR (1) HRP20030420A2 (pl)
HU (1) HUP0302160A3 (pl)
IL (1) IL155704A0 (pl)
IS (1) IS6786A (pl)
MA (1) MA26964A1 (pl)
MX (1) MXPA03004870A (pl)
NO (1) NO20032441L (pl)
OA (1) OA12534A (pl)
PA (1) PA8534101A1 (pl)
PE (1) PE20020597A1 (pl)
PL (1) PL365927A1 (pl)
PT (1) PT1337271E (pl)
SK (1) SK6192003A3 (pl)
SV (1) SV2003000751A (pl)
TN (1) TNSN01169A1 (pl)
UY (1) UY27042A1 (pl)
WO (1) WO2002043762A2 (pl)
ZA (1) ZA200303381B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
ES2265040T3 (es) 2001-05-25 2007-02-01 Warner-Lambert Company Llc Composicion farmaceutica liquida.
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
MXPA06011322A (es) * 2004-04-02 2007-02-21 Impax Laboratories Inc Formas de dosificacion farmaceutica que tienen propiedades de liberacion inmediata y/o liberacion controlada que contienen un agonista del receptor gabab.
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
MX2007010076A (es) 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
EP2142529B1 (en) * 2007-04-27 2013-12-25 Purdue Pharma LP Trpv1 antagonists and uses thereof
US20100279984A1 (en) * 2007-10-09 2010-11-04 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or one more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
CN107050456B (zh) * 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
RS55701B1 (sr) 2011-06-22 2017-07-31 Purdue Pharma Lp Trpv1 antagonisti koji uključuju dihidroksi supstituent i njihove upotrebe
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
MX2021013511A (es) * 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
PL124029B1 (en) 1979-06-01 1982-12-31 Wellcome Found Process for preparing novel derivatives of 1,2,4-triazine
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
WO2000050034A1 (en) * 1999-02-24 2000-08-31 The Regents Of The University Of California Gaba receptors mediate inhibition of t cell responses
PL350884A1 (en) * 1999-04-01 2003-02-10 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
ATE264311T1 (de) * 1999-04-01 2004-04-15 Pfizer Prod Inc Verbindungen zur behandlung und vorsorge bei diabetes

Also Published As

Publication number Publication date
OA12534A (en) 2006-06-05
MXPA03004870A (es) 2003-08-19
DOP2001000289A (es) 2003-02-15
PA8534101A1 (es) 2002-10-31
AP2001002360A0 (en) 2001-12-31
NO20032441D0 (no) 2003-05-28
AR031431A1 (es) 2003-09-24
WO2002043762A2 (en) 2002-06-06
HUP0302160A3 (en) 2005-05-30
CZ20031399A3 (cs) 2004-04-14
BG107774A (en) 2004-01-30
EP1337271B1 (en) 2004-11-03
ATE281181T1 (de) 2004-11-15
EA200300432A1 (ru) 2003-10-30
ECSP034624A (es) 2003-07-25
PT1337271E (pt) 2005-01-31
DE60106968T2 (de) 2005-11-03
HUP0302160A2 (hu) 2003-11-28
SV2003000751A (es) 2003-01-13
US6544998B2 (en) 2003-04-08
UY27042A1 (es) 2002-07-31
IL155704A0 (en) 2003-11-23
AU2002215159A1 (en) 2002-06-11
MA26964A1 (fr) 2004-12-20
BR0115783A (pt) 2003-09-16
CR6964A (es) 2004-02-02
HRP20030420A2 (en) 2004-08-31
KR20030059290A (ko) 2003-07-07
SK6192003A3 (en) 2004-07-07
IS6786A (is) 2003-04-14
CN1477975A (zh) 2004-02-25
TNSN01169A1 (fr) 2005-11-10
ZA200303381B (en) 2004-04-30
NO20032441L (no) 2003-07-03
EP1337271A2 (en) 2003-08-27
EE200300248A (et) 2003-10-15
US20020091128A1 (en) 2002-07-11
DE60106968D1 (de) 2004-12-09
WO2002043762A3 (en) 2003-03-13
PE20020597A1 (es) 2002-07-08
JP2004514699A (ja) 2004-05-20
ES2230378T3 (es) 2005-05-01
CA2430298A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
IL155704A0 (en) Combination of gaba agonists and sorbitol dehydrogenase inhibitors
IL155710A0 (en) Combination of gaba agonists and aldose reductase inhibitors
GB0025782D0 (en) Use of inhibitors
EP1383743A4 (en) DOUBLE INHIBITORS OF PDE 7 AND PDE 4
AU8969601A (en) New use of lipase inhibitors
AU8212901A (en) Deacetylase inhibitors
IL152753A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL152078A0 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
SI1251848T1 (en) Gyrase inhibitors and uses thereof
PT2270005E (pt) Pró-fármaco de um inibidor de ice
HUP0300061A3 (en) Use of il-18 inhibitors
PL353535A1 (en) Application of selective pde 10 inhibitor and application of papaverine
GB0018164D0 (en) Corrosion inhibitors
GB0030284D0 (en) Enzyme inhibitors
AU2002214038A1 (en) Inhibitors of transglutaminases
HUP0204376A3 (en) Novel invertase inhibitors and methods of use
GB0004299D0 (en) Corrosion inhibitors
IL154927A0 (en) Combination of statins and sorbitol dehydrogenase inhibitors
SI1337271T1 (en) Combination of gaba agonists and sorbitol dehydrogenase inhibitors
AU1212002A (en) Use of lipase inhibitors
AU4587901A (en) Bisubstrate inhibitors of kinases
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
ZA200205471B (en) Use of IL-18 inhibitors.
AU2001249794A1 (en) Hemoglobinase inhibitors and methods of use
DK1337271T3 (da) Kombination af GABA-agonister og sorbitoldehydrogenaseinhibitorer

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)